WEBINAR | Executing MRD in Oncology Trials: From Protocol Design to Commercial Impact
In this session, Syneos Health experts were joined by MRD experts to explore how sponsors can incorporate MRD across early-phase and registrational development, with a focus on regulatory positioning, clinical pharmacology implications and overall clinical strategy.
In this session, Syneos Health experts were joined by Rob Lentz, MD, and David Shames, PhD, from Natera, to explore how sponsors can incorporate MRD across early-phase and registrational development, with a focus on regulatory positioning, clinical pharmacology implications and overall clinical strategy
When you watch this webinar, you’ll gain real-world insights on:
- Translating MRD strategy into executable trial design, including protocol structure, site selection, assay logistics and data quality planning
- Understanding how cross-functional alignment across medical, operations and scientific teams drives investigator adoption and consistent execution
- Seeing how early operational decisions around MRD can shape regulatory positioning, market access strategy and commercial differentiation
Whether you are exploring MRD as an emerging biomarker or actively embedding it into your oncology strategy, this webinar recording will help you translate complexity into confident, data-driven development decisions.
Related Content
Looking for exclusive insight?
